Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Sporozoite Challenge Study to Assess the Safety, Immunogenicity and Protective Efficacy of Adjuvanted R21, Administered in Different Dose Schedules in Healthy UK Volunteers

NCT03970993 is registered in ClinicalTrials.gov with University of Oxford as lead sponsor.

NCT NCT03970993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03970993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Sporozoite Challenge Study to Assess the Safety, Immunogenicity and Protective Efficacy of Adjuvanted R21, Administered in Different Dose Schedules in Healthy UK Volunteers
Lead sponsor
University of Oxford
Phase
Phase 1/2
Overall status
Completed
Start date
June 17, 2019
Completion date
August 24, 2021
Enrollment
78 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

malaria